Trial · NCT02988973
Registered outcomes36
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 36
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in the average Hemoglobin (Hb) | Baseline and Weeks 18 to 24 | |
| Secondary | Average Hb from Week 18 to Week 24 | Up to Week 24 | |
| Secondary | Number of Participants Who Achieved the Average Hb level of 10.0 to 12.0 g/dL For Weeks 18 to 24 | Weeks 18 to 24 | |
| Secondary | Number of participants who achieve the target Hb level at each week | Up to Week 24 | |
| Secondary | Change from baseline in Hb to each post-dosing time point | Baseline and Up to Week 52 | |
| Secondary | Proportion of time points that achieve the target Hb level from Weeks 18 to 24 | Up to Week 24 | |
| Secondary | Rate of rise in Hb levels (g/dL/week) from week 0 to at the earliest date of week 4, time of discontinuation, or time of dose adjustment | Up to Week 4 | |
| Secondary | Quality of life assessed by SF-36 | Up to Week 52 | SF-36: Medical Outcomes Study 36-Item Short-Form Health Survey |
| Secondary | Quality of life assessed by EQ-5D-5L | Up to Week 52 | EQ-5D: EuroQol 5 Dimension 5 Levels |
| Secondary | Quality of life assessed by WPAI:ANS | Up to Week 52 | WPAI:ANS: Work Productivity and Activity Impairment Questionnaire: Anaemic Symptoms |
| Secondary | Quality of life assessed by FACT-An | Up to Week 52 | FACT-An: Functional Assessment of Cancer Therapy-Anemia |
| Secondary | Average Hb from weeks 44 to 52 | Up to Week 52 | |
| Secondary | Change from baseline in the average Hb from weeks 44 to 52 | Baseline and Up to Week 52 | |
| Secondary | Number of Participants Who Achieved the Average Hb level of 10.0 to 12.0 g/dL For Weeks 44 to 52 | Weeks 44 to 52 | |
| Secondary | Number of participants who achieve the target Hb level at each week | Up to Week 52 | |
| Secondary | Proportion of time points that achieve the target Hb level from Weeks 44 to 52 | Up to Week 52 | |
| Secondary | Average Hematocrit Level | Up to Week 52 | |
| Secondary | Average Reticulocyte Level | Up to Week 52 | |
| Secondary | Average Ferrum Level | Up to Week 52 | |
| Secondary | Average Ferritin Level | Up to Week 52 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02988973/registered